Taste Profile and Relative Bioavailability of Tovorafenib Powder for Oral Suspension and Food Effect of the Tovorafenib Tablet in Healthy Participants.

Yang Zhang, Mike Preigh, Jing Wang, Eleni Venetsanakos, Yujin Wang, Elly Barry, Don Corson

Abstract readRandomized Controlled TrialClinical Trial, Phase I

In one paragraph

Trial report in Clinical pharmacology in drug development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Cellular Context Influences Kinase Inhibitor Selectivity.Journal of medicinal chemistry · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yang ZhangClinical Pharmacology, Day One Biopharmaceuticals, Inc., Brisbane, CA, USA.

Mike PreighChemistry, Manufacturing, and Controls, Day One Biopharmaceuticals, Inc., Brisbane, CA, USA.

Jing WangClinical Pharmacology, Day One Biopharmaceuticals, Inc., Brisbane, CA, USA.

Eleni VenetsanakosTranslational Sciences, Day One Biopharmaceuticals, Inc., Brisbane, CA, USA.

Yujin WangClinical Pharmacology, Day One Biopharmaceuticals, Inc., Brisbane, CA, USA.

Elly BarryClinical Development, Day One Biopharmaceuticals, Inc., Brisbane, CA, USA.

Don CorsonChemistry, Manufacturing, and Controls, Day One Biopharmaceuticals, Inc., Brisbane, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A pediatric-friendly powder for oral suspension (PfOS) of tovorafenib, a type II RAF inhibitor, was developed for patients with difficulty swallowing tablets. This open-label, randomized, phase 1 study (QSC205140) evaluated the taste/palatability of PfOS formulations (n = 12), the relative bioavailability of the PfOS versus tablet formulation, and the food effect on tablets (n = 12) in healthy participants. Tovorafenib was initially administered at 300 mg and reduced to 100 mg due to musculoskeletal adverse events (AEs). The addition of sweetener and/or flavoring improved taste/palatability. Geometric mean ratios (90% confidence interval) of dose-corrected peak plasma drug concentration (C

Indexed as

Food-Drug InteractionsTasteAdministration, OralAdultArea Under CurveBiological AvailabilityFemaleHealthy VolunteersHumansMaleMiddle AgedPowdersSuspensionsTabletsYoung AdultPowdersSuspensionsTabletsfood effectpediatricrelative bioavailabilitytaste and palatabilitytype II kinase inhibitor

Identifiers

PMID40536406

DOI10.1002/cpdd.1558

PMCPMC12402836

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.